What Does Wall Street Think About Krystal Biotech (KRYS)?
Krystal Biotech, Inc. (NASDAQ:KRYS) is one of the best strong buy growth stocks to buy according to hedge funds. On January 12, Citi lifted the price target on Krystal Biotech, Inc. (NASDAQ:KRYS) to $336 from $320 and maintained a Buy rating on the shares. The rating update came after Krystal Biotech, Inc. (NASDAQ:KRYS) announced selected preliminary unaudited 2025 financial results on January 11, including fourth quarter and full year 2025 VYJUVEK® net product revenue.
For fiscal Q4 2025, the company announced that it expects net product revenue for VYJUVEK to be between $106 million and $107 million, based on preliminary unaudited financial information. VYJUVEK’s net revenue for the full year 2025 is anticipated to be between the range of $388 million and $389 million. Krystal Biotech, Inc. (NASDAQ:KRYS) further reported that cash, cash equivalents, and investments are around $955 million as of December 31, 2025.
The company clarified that the preliminary unaudited results are based on the initial analysis of operations conducted by the management for the year ended December 31, 2025, and are subject to adjustment. Krystal Biotech, Inc. (NASDAQ:KRYS) is set to report its full financial results for fiscal Q4 and full year 2025 in February 2026.
Krystal Biotech, Inc. (NASDAQ:KRYS) is a biotechnology company that develops and commercializes pharmaceutical products and offers the product VYJUVEK, which is a topical gel that treats wounds in adult and pediatric patients (from birth) with dystrophic epidermolysis bullosa (DEB).
While we acknowledge the potential of KRYS as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.
Disclosure: None. This article is originally published at Insider Monkey.
